Piramal Pharma Ratios

Piramal Pharma Ltd Ratios

The Piramal Pharma Ltd Ratios page provides a complete fundamental analysis of Piramal Pharma Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Piramal Pharma Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Piramal Pharma Ltd (NSE: PPLPHARMA, BSE: 543635) is currently trading at ₹138.35, with a market capitalization of ₹183.77B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Piramal Pharma Ltd remains a key stock for fundamental analysis using Piramal Pharma Ltd Ratios.

Piramal Pharma Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Piramal Pharma Ltd P/E ratio currently stands at 327.83, making it one of the most tracked metrics in Piramal Pharma Ltd Ratios.

Historically, the Piramal Pharma Ltd P/E ratio has shown strong fluctuations:

• 2024: 327.83
• 2023: 928.67
• 2022: 0
• 2021: 0

The decline in Piramal Pharma Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Piramal Pharma Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 3.65.

Historical P/B trend:

• 2024: 3.65
• 2023: 2.16
• 2022: 1.21
• 2021: 0

Piramal Pharma Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Piramal Pharma Ltd P/S ratio currently stands at 3.27, an important part of Piramal Pharma Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 3.27
• 2023: 2.02
• 2022: 1.15
• 2021: 0

The rising Piramal Pharma Ltd P/S ratio indicates improved revenue valuation by investors.

Piramal Pharma Ltd Price to Cash Flow Ratio (P/CF)

The Piramal Pharma Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 59.72.

Historical Piramal Pharma Ltd Price to Cash Flow Ratio:

• 2024: 59.72
• 2023: 29.29
• 2022: 28.25
• 2021: 0

The rising Piramal Pharma Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Piramal Pharma Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Piramal Pharma Ltd EV currently stands at ₹341.96B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 341.96B
• 2023: 206.27B
• 2022: 130.46B
• 2021: 0

Piramal Pharma Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Piramal Pharma Ltd EV/EBITDA ratio is currently 22.54, a key metric in Piramal Pharma Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 22.54
• 2023: 16.37
• 2022: 20.36
• 2021: 0

Higher Piramal Pharma Ltd EV/EBITDA suggests premium valuation.

Piramal Pharma Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Piramal Pharma Ltd D/E ratio is currently 0.60, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.60
• 2023: 0.60
• 2022: 0.83
• 2021: 0.62

Piramal Pharma Ltd maintains moderate leverage with manageable risk.

Return on Equity (ROE %)

The Piramal Pharma Ltd ROE currently stands at 1.14%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 1.14
• 2023: 0.24
• 2022: -2.77
• 2021: 0

Declining ROE indicates pressure on profitability.

Piramal Pharma Ltd Ratios Analysis Summary

The Piramal Pharma Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Piramal Pharma Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Piramal Pharma Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.